Sign In
Buy IONS
$56.75
-1.50 (-2.58%)
At Close: Jul 13, 2026
Marshall Wace LLP Purchases 455 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
11:12am, Sunday, 05'th Apr 2020
Marshall Wace LLP lifted its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 81.1% during the fourth quarter, according to the company in its most recent disclosure with the Securitie
Janus Henderson Group PLC Sells 380,819 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
10:04am, Sunday, 05'th Apr 2020
Janus Henderson Group PLC lessened its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 65.4% during the fourth quarter, according to the company in its most recent filing with the Securities &
Geode Capital Management LLC Grows Holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
10:54am, Saturday, 04'th Apr 2020
Geode Capital Management LLC raised its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Expected to Announce Quarterly Sales of $169.97 Million
09:00am, Saturday, 04'th Apr 2020
Equities research analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post $169.97 million in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Ionis Phar
SVB Leerink Weighs in on Ionis Pharmaceuticals Inc's Q1 2020 Earnings (NASDAQ:IONS)
06:00am, Saturday, 04'th Apr 2020
Ionis Pharmaceuticals Inc (NASDAQ:IONS) – SVB Leerink lowered their Q1 2020 earnings estimates for shares of Ionis Pharmaceuticals in a report issued on Tuesday, March 31st. SVB Leerink analyst M. F
Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic
12:33am, Saturday, 04'th Apr 2020
Last month French biotech Dynacure dosed the first patient in an early-stage trial of its lead drug candidate, a treatment for a group of rare genetic
Analysts' Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Minerva Neurosciences (NERV) and
Analysts’ Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (
SGEN
–
Research Report
), Minerva Neurosciences (
NERV
–
Research Report
) and O
Vericel (VCEL) Gets a Hold Rating from Needham
07:01pm, Thursday, 02'nd Apr 2020
In a report released today, Chad Messer from Needham maintained a Hold rating on Vericel (VCEL). The company's shares closed last Thursday at $8.48, close
Vericel (VCEL) Gets a Hold Rating from Needham
07:01pm, Thursday, 02'nd Apr 2020
In a report released today,
Chad Messer
from Needham maintained a
Hold
rating on Vericel (
VCEL
–
Research Report
). The company’s shares closed last Thursday at $8.48, close to its 52-week low of
Needham Keeps Their Buy Rating on Seattle Genetics (SGEN)
06:51pm, Thursday, 02'nd Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Seattle Genetics (SGEN) today and set a price target of $144.00. The company's shares closed last
Needham Keeps Their Buy Rating on Seattle Genetics (SGEN)
06:51pm, Thursday, 02'nd Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Seattle Genetics (SGEN – Research Report) today and set a price
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA (nusinersen)in Phase 2/3 DEVOTE Study
11:30am, Thursday, 02'nd Apr 2020
Biogen (BIIB) today announced that the first patient has been treated in the global clinical study, DEVOTE. The study is designed to evaluate the safety, tolerability and potential for even greater e
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA (nusinersen)in Phase 2/3 DEVOTE Study
11:30am, Thursday, 02'nd Apr 2020
DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy...
Analysts Expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to Announce -$0.05 EPS
07:46am, Thursday, 02'nd Apr 2020
Brokerages predict that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report earnings of ($0.05) per share for the current quarter, according to Zacks Investment Research. Seven analysts have made esti
